10x Genomics (NASDAQ: TXG) CEO sells 15,000 shares under Rule 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
10x Genomics, Inc. CEO Serge Saxonov reported open‑market sales of 15,000 shares of Class A Common Stock. He sold 10,000 shares on March 23, 2026 at a weighted average price of $19.1297 per share and 5,000 shares on March 24, 2026 at a weighted average price of $19.5223 per share.
The filing states these transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 29, 2025. After the sales, he directly holds 1,172,273 shares of Class A Common Stock and also has significant additional indirect and Class B holdings held through various trusts where he serves as trustee, with each Class B share convertible into one Class A share.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 15,000 shares ($288,909)
Net Sell
8 txns
Insider
Saxonov Serge
Role
Chief Executive Officer
Sold
15,000 shs ($289K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 5,000 | $19.5223 | $98K |
| Sale | Class A Common Stock | 10,000 | $19.1297 | $191K |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 1,172,273 shares (Direct);
Class B Common Stock — 1,100,927 shares (Direct);
Class B Common Stock — 180,938 shares (Indirect, See footnote);
Class A Common Stock — 27 shares (Indirect, See footnote)
Footnotes (1)
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. This transaction was executed in multiple trades at prices ranging from $18.78 to $19.41, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Reflects the transfer by the Reporting Person of 13,644 shares of Class A Common Stock to the Y/S Pot Trust on March 3, 2026. This transaction was executed in multiple trades at prices ranging from $19.49 to $19.59, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. Reflects the transfer by the Reporting Person of 91,113 shares of Class B Common Stock to the Sirius Trust on March 3, 2026. The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee. 250,000 shares are held by each of Polaris 2018 Irrevocable Trust, Antares 2018 Irrevocable Trust, Arcturus 2018 Irrevocable Trust, FLY 2018 Irrevocable Trust, LY 2018 Irrevocable Trust, MS 2018 Irrevocable Trust and NS 2018 Irrevocable Trust, of which the Reporting Person is the sole trustee.
FAQ
What insider transactions did 10x Genomics (TXG) CEO Serge Saxonov report?
Serge Saxonov reported selling 15,000 shares of Class A Common Stock. He sold 10,000 shares on March 23, 2026 and 5,000 shares on March 24, 2026 in open‑market transactions at weighted average prices around $19 per share.
How are Serge Saxonov’s trust holdings in 10x Genomics (TXG) structured?
Many shares are held in various trusts where Serge Saxonov serves as trustee. These include the Andromeda Trust, Y/S Descendants' Trust, Y/S Pot Trust, Sirius Trust and several 2018 irrevocable trusts, reflecting substantial additional indirect and Class B holdings.